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During apoptosis, engagement of the mitochondrial pathway involves the permeabilization of the outer mitochondrial membrane (OMM),
which leads to the release of cytochrome c and other apoptogenic proteins such as Smac/DIABLO, AIF, EndoG, Omi/HtraA2 and DDP/TIMM8a.
OMM permeabilization depends on activation, translocation and oligomerization of multidomain Bcl-2 family proteins such as Bax or Bak.
Factors involved in Bax conformational change and the function(s) of the distinct domains controlling the addressing and the insertion of Bax into
mitochondria are described in this review. We also discuss our current knowledge on Bax oligomerization and on the molecular mechanisms
underlying the different models accounting for OMM permeabilization during apoptosis.
© 2006 Elsevier B.V. All rights reserved.Keywords: Apoptosis; Bax; Activation; Conformational change; Addressing/targeting; Permeabilization; Mitochondrion“Life is pleasant, death is peaceful. It's the transition that's
troublesome”
(Isaac Asimov)
Apoptosis is a cell death program that is central to cellular
and tissue homeostasis, involved in many physiological and
pathological processes [1]. The proteins of the Bcl-2 family are
key regulators of this program and their main function is to
control mitochondrial permeability and particularly, the release
of apoptogenic proteins from this organelle [2].
The Bcl-2 family of proteins can be divided into three groups
based on their structure and their role in apoptosis (Fig. 1):Abbreviations: ANT, adenosine nucleotide translocator; AIF, Apoptosis
inducing factor; ART, Apoptosis Regulation of Targeting; BdGBM, Bax-
deficient Glioblastoma Multiforme; Bif-1, Bax interacting factor 1; BH, Bcl-2
homology; BOPs, BH3-only proteins; BimEL, extra long isoform of Bim; GFP,
green fluorescent protein; Hα, α helix;Hn, Humanin; MAC, Mitochondrial
Apoptosis-induced Channel; Δψm, mitochondrial change in potential; mPTP,
mitochondrial permeability Transition Pore; OMM, outer mitochondrial
membrane; PI3, phosphatidylinositol 3; tBid, truncated form of Bid; VDAC,
voltage dependent anionic channel
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doi:10.1016/j.bbabio.2006.05.032– The anti-apoptotic proteins like Bcl-2, Bcl-xL, Bcl-w, Mcl-1,
A1/Bfl-1, NR-13, Boo/Diva/Bcl-2-L-10, Bcl-B, E1B 19K
(adenovirus), BHFR1 (Epstein Barr virus), CED-9 (C. ele-
gans). These proteins are characterized by the presence of
four Bcl-2 homology domains (BH: BH1, BH2, BH3 and
BH4) (Fig. 1).
– The pro-apoptotic proteins such as Bax, Bak, Bok/Mtd and
Bcl-Xs, which contain three homology domains BH1, BH2
and BH3.
– The BH3-only proteins (BOP), which include Bid, Bad,
Noxa, Puma, Bmf, BimL/Bod, Bik/Nbk, Blk, Hrk/DP5,
Bnip3 and Bnip3 L. These proteins induce apoptosis by
activating pro-apoptotic proteins like Bax or by inhibiting
anti-apoptotic proteins like Bcl-2.
Most of these proteins contain a C-terminal hydrophobic α-
helix, which is a potential transmembrane domain involved in
their localization to the membranes of organelles such as the
mitochondria, the endoplasmic reticulum and the nucleus [3,4].
These proteins can form homo-dimers and/or hetero-dimers
[5,6], essentially through the interaction of their BH3 domain
[7]. The BH4 domain that corresponds to the first α helix (Hα1)
Fig. 1. Representation of all the known mammalian Bcl-2 family members. Bcl-2 homology regions 1–4 (BH1–4) are indicated. TM indicates a putative
transmembrane region that mediates localization to intracellular membranes. α: Hα. The Hα5–Hα6 overlapping region containing the BH1 domain corresponds to the
pore-forming region based on structural homology with bacterial toxins. The BH3 domain in the pro-apoptotic members is a ligand for the hydrophobic pocket formed
by the BH1–BH3 domains of the anti-apoptotic members.
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their anti-death functions [8,9].
1. Cellular localization of Bax
The activation of Bax during apoptosis usually does not
require an increase transcription of its gene. Cell fractionation
and confocal microscopy showed a preferential cytosolic
localization of Bax in most cells in spite of the presence of
the C-terminal putative transmembrane domain similar to that
of Bcl-2 [10–12]. NMR data on the 3-D structure of soluble
Bax showed that the C-terminal hydrophobic Hα9 is bent in
a hydrophobic groove. Although Hα9 is essentially com-
posed of hydrophobic amino acids, it also contains severalpolar amino acids (Thr172, Thr174, Thr182, Ser184,
Thr186). Except Ser184, all are exposed to the solvent and
thus may contribute to the solubility of Bax in this
conformation [13]. On the other hand, the N-terminus is
also essential to keep the cytosolic conformation of Bax as a
deletion of the first 20 amino acids results in a constitutive
mitochondrial localization [14,15]. However, the cytosolic
localization of Bax has not been unanimously observed and
some groups describe a constitutive mitochondrial localiza-
tion of Bax in healthy cells [16]. Of note, the activation of
mitochondria-bound Bax requires additional partners such as
c-myc-regulated elements [17,18], and thus can be disso-
ciated from the mitochondrial addressing step, at least in
some cells.
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the OMM
The mitochondrial form of Bax found in non-apoptotic cells
is a 21 kDa monomer weakly associated with the OMM or
soluble in the cytosol. Upon the induction of apoptosis, this
monomer evolves into a high molecular complex (96 to
260 kDa) inserting into the OMM, suggesting that an
oligomerization accompanies this insertion, see, for example
[19–21]). These complexes appear to be homo-oligomers of 6
to 8 molecules of Bax as observed in gel-filtration assays on
isolated mitochondria. This oligomerization seems to be an
important step in the activation of Bax. Electron microscopy
indicates that Bax translocation to the OMM is the first step in
Bax activation and that the mitochondria-associated oligomer
is the biologically active pro-apoptotic structure [22].
1.2. Bax conformational changes, addressing to mitochondria
and insertion into the OMM
Data have shown that the BH3 domain of inactive/soluble
Bax is inaccessible for the oligomerization events [13]. Indeed,
Bax translocation to the OMM during apoptosis assumes the
unfolding of the Hα9 from its hydrophobic groove and a change
in the conformation in the N-terminus of the protein [23]. Thus,
Bax would undergo one or more conformational change(s)
during its activation leading to its anchoring in the OMM and its
oligomerization. Two models have been proposed to explain the
activation of Bax during apoptosis. The first model suggests that
Bax, constitutively associated with the OMM, undergoes a
conformational change upon induction of apoptosis leading to
oligomer formation and anchoring into the OMM [16]. The
second model suggests that a conformational change in Bax
occurs in the cytosol resulting in the opening of the C-terminal
Hα9 causing the exposure of the pore forming domain Hα5–
Hα6 and probably also the accessibility of the BH3 domain andFig. 2. Crucial amino acids and domains involved in Bax functions and/or mitocho
homology with Bcl-2. C-term indicates the terminal alpha helix which has been sug
sequences of the alpha helices Hα1, Hα5, Hα6, Hα9 are represented in the single let
labeled in red.only then Bax is addressed to the mitochondria through its N-
terminus [24] or its C-terminus [25,26]. Recently, Annis et al.
[27] showed that Bax is actually inserted into membranes as a
monomer implying that the insertion step occurs prior to
oligomerization.
The hydropathy profile of Hα9 suggests that it could be a
putative anchoring domain. The role of these 21 amino acids
in the C-terminal domain was first studied by deletion
mutagenesis. Studies based on the cellular localization of the
fusion protein green fluorescent protein (GFP)-BaxΔC
showed that a deletion of 21, 10 or 5 amino acids from the
C-terminal generates a protein that is strictly cytosolic under
apoptotic conditions [11,23]. These data suggest that the Hα9
plays an essential role in anchoring Bax into the OMM. The
crucial role of the conformation of Hα9 was investigated by
analyzing different substitutions at Ser184, the polar residue in
Hα9 facing the protein core. A substitution by Asp, Gln or
Lys generates a protein exclusively cytosolic whereas the
deletion of Ser184 or a substitution by Val or Ala produces to
a cytotoxic protein exclusively localized to the OMM [23].
Moreover, the BaxΔSer184 mutant fused to GFP exhibited a
higher affinity for mitochondria. In order to determine if the
C-terminus of Bax is a mitochondrial insertion sequence,
cytosolic proteins were fused to this domain. It was showed
that GFP fused to the last 21 amino acids of Bax (GFP-21)
does not co-localize to the OMM even during apoptosis
whereas the same construct with a Ser184 deletion (GFP-20)
inserted into the OMM [23]. The central role of the
conformation of Hα9 has been further underlined by
substitution of Pro168 located in the loop preceding the
Hα9 (Fig. 2). Data by Borner's group suggested that this
residue was essential for the targeting of Bax to the
mitochondria [25,26]. However, we have recently observed
that this Pro was more likely involved in the control of Bax
membrane-integration by occluding the Hα5 and Hα6 “pore
forming” domain [24,28].ndrial targeting. Bcl-2 homology regions are indicated based on their structural
gested to be the transmembrane/addressing signal (see ref 25). The amino acid
ter code. Crucial amino acids involved in Bax translocation and/or activation are
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the control of Bax-addressing and insertion also involves the N-
terminus. The implication of the N-terminal domain was
suggested by experiments on epitope exposure after Bax
activation. This region shows a differential affinity to N-
terminal specific antibodies before and after Bax activation
implying that this domain undergoes crucial changes during
apoptosis. The 6A7 antibody does not recognize the soluble
cytosolic form of Bax but interacts with the mitochondrial or
oligomeric forms [22,23]. Numerous studies have revealed that
Bax deleted of 19 amino acids in its N-terminus (BaxΔART,
Apoptosis Regulation of Targeting) constitutively inserts into
the OMM [14,15,24,29–31]. The role of the Pro residues
located at position 8 and 13 within the ART might be crucial.
Indeed, site-directed mutagenesis experiments have shown that
Pro13 was decisive for the maintenance of the cytosolic Bax
conformation and that a substitution for Val increased its
apoptogenecity [32]. This substitution Pro13Val caused con-
formational changes in soluble Bax, a strong binding of Bax to
mitochondria and an enhancement of its oligomerization.
Similarly, the simultaneous replacement of both Pro residues
by Gly stimulates Bax translocation to the OMM in S.
cerevisiae [28].
The association of Bax with microsomal or mitochondrial
membranes using a cell-free system showed that contrary to
Bcl-2, Bax bound poorly to these organelles [29]. Deletion of
the C-terminus of Bax (BaxΔC) or exchanging the C-terminus
of Bax and Bcl-xL shows that, unlike that of Bxl-xL, the C-
terminus of Bax is not an addressing/anchoring signal.
Furthermore, the consequence of a deletion of the C-terminus
was investigated in yeast strains that co-expressed truncated
forms of Bax (i.e., BaxΔC) and Bcl-xL (i.e., Bcl-xLΔC) and
showed that BaxΔC was as efficient as full-length Bax in
promoting cytochrome c release [30]. Moreover, it was reported
that a substitution of the C-terminus of Bax by that of Bcl-xL
(BaxΔCxL) does not modify its sub-cellular localization and its
association with mitochondria in human and rat cells or in S.
cerevisiae but abrogated its pro-apoptotic properties [33].
Overall, these results suggest that the C-terminus of Bax plays
an important role in apoptosis but not in the addressing/
targeting to the mitochondria. Moreover, Bax or BaxΔC over-
expression in BdGBM (Bax-deficient Glioblastoma Multi-
forme) cells enhanced their sensitivity to apoptosis, which was
enhanced by that of BaxΔART or the combined deletion of the
2 extremities (BaxΔARTΔC) [24]. Likewise, there is a natural
variant of Bax α, Bax Ψ, which lacks the N-terminus that is
constitutively localized to mitochondria and is a more powerful
inducer of apoptosis than Bax α [34]. Taken together these
results indicate that both the N- and the C-termini functionally
interact to control the activity of Bax and thus constitute two
distinct ART domains as shown in yeast model by Arokium et
al. [28].
Pro-apoptotic activity assays and localization studies by
confocal microscopy of several N-terminal mutants of Bax α
and Bax Ψ and chimera constructs indicated that the Hα1
corresponding to amino acids 20–37, is implicated in Bax
targeting to mitochondria. Deletion of Hα1 impairs the bindingof Bax α to mitochondria whereas a fusion of the N-terminus of
Bax αwith the cytosolic protein RFP (Red Fluorescent Protein),
results in the binding of the chimera proteins to mitochondria
both in cell-free assays and in vitro. In addition, a fusion protein
Hα1-RFP has a mitochondrial localization, whereas the RFP-
Hα9 remained cytosolic. The Hα1-RFP construct associated
with mitochondria but was sensitive to an alkali treatment,
suggesting that Hα1 was not an anchoring domain but an
addressing sequence. Furthermore, a Leu26Gly substitution
within the Hα1 significantly decreased the acellular association
of in vitro translated Bax α and Bax Ψ mutants with
mitochondria and also affected their in vivo mitochondrial
localization [34]. Mutations in the Hα1 also blocked the
subsequent activation of the execution phase of apoptosis.
Conversely, a deletion of the C-terminus does not appear to
influence Bax α and Bax Ψ mitochondrial addressing. It can
thus be concluded that the N-terminal domain determines the
addressing of Bax to mitochondria, while the C-terminal
domain is involved in the maintenance of the inactive form of
Bax. The pro-apoptotic activity of Bax is thus regulated by the
conformation of both extremities.
The third important domain in the process of Bax-
translocation to the OMM is formed by the central amphipathic
helices Hα5 and Hα6, which are the putative pore forming
domain of Bax as shown by Nouraini et al. [35]. Bax seems to
insert into the OMM following a model already described for
bacterial toxins, with the hydrophilic surfaces of Hα5 and Hα6
facing each other and the hydrophobic sides facing the liquid
phase [13,36]. A recent study demonstrated the role of Hα5 and
Hα6 as a transmembrane domain of Bax [37]. All these data
suggest that Hα9 might not be the only domain involved in the
membrane insertion of Bax (see ref. [25] for an alternative
view).
1.3. Regulation of Bax by phosphorylation
Both anti- and pro-apoptotic Bcl-2 family members may be
controlled by phosphorylation [38–40]. Several studies have
reported a MEK1 or Akt regulation of Bax activation in diverse
cellular systems [41–44]. A recent study has indicated that Akt
kinase directly prevented Bax translocation to mitochondria via
a phosphorylation of Ser184 [45]. It was reported that Bax
conformational changes were sensitive to glucose metabolism
and that Akt could prevent Bax activation and apoptosis by
promoting glycolysis through multiple post-transcriptional
mechanisms [43]. This phosphorylation required the PI3
kinase/Akt-pathway activation and appeared to be mediated
by Akt itself. Akt-dependent phosphorylation of Bax promoted
its sequestration to the cytoplasm, as phosphorylated Bax could
not be immunoprecipitated with the conformation-specific
antibody 6A7, indicating that phosphorylation maintained Bax
in an inactive form. This phosphorylated Bax was shown to
hetero-dimerize with Mcl-1, Bcl-xL and A1 in the cytoplasm of
neutrophils [45]. Another recent study reported that nicotine
could inactivate the pro-apoptotic function of Bax also through
phosphorylation of Ser184 [46]. In contrast, Linseman et al.
[47] demonstrated that a phosphorylation of Ser163 stimulated
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the mitochondria.
Thus depending on the nature of the stimulus and/or site of
phosphorylation (i.e., Ser163 or Ser184), Bax could be
activated or inactivated. These results could have a very
significant impact on the design of therapeutic strategies
modulating apoptosis.
1.4. How apoptotic signals trigger Bax mobilisation/
activation?
1.4.1. pH and temperature
It was reported that Bax activation and variations in the pH
occurred in parallel during apoptosis [48,49]. For example,
staurosporine or TNFα treatment of HeLa cells was
accompanied by intracellular pH variations and Bax activation
[48]. Furthermore, it was shown that a low pH promoted
dimerization among Bcl-2 family proteins, suggesting that a
conformational change occurred [50]. A recent study by our
group showed that pH could induce a conformational change
in Bax resulting in the N-terminal and BH3 domain being
exposed leading to mitochondrial insertion and oligomeriza-
tion [51]. Cell-free experiments have shown that in the pH
range of 6.8 to 7.8, Bax bound poorly to mitochondria
whereas at pH 8.2 or 6, Bax binding to mitochondria was
significantly increased [52]. Immunoprecipitation analyses
have suggested that pH changes could induce two major
alterations in the conformation of Bax. The first occurs at a pH
between 6 and 6.8 or between 7.6 and 8, resulting in exposure
of the BH3 domain. The second occurs at a pH <6 or >8,
causing the N-terminus, which contains the addressing signal
to be exposed [52]. These results suggest that high or low pH
can induce a change in the conformation of Bax leading to its
activation.
Several recent studies reported that heat could also induce
Bax conformational changes and apoptosis [53–55]. It was
shown that high temperatures (42–45 °C) induced apoptosis
whereas mild heat stress-induced thermotolerance in CHO and
human adenocarcinoma cells [54]. Heat shock-induced apop-
tosis was associated with mitochondrial membrane potential
decrease, Bax translocation to mitochondria, cytochrome c
release and caspase 3 activation in normal cells whereas
thermotolerant cells, that over-expressed heat shock proteins
(Hsps) 27, 32, 70 and 90 were resistant. It was also reported
that heat treatment of cells for 1 h at 43 °C resulted in Bax
activation, as demonstrated by immunofluorescence analyses
using a conformation specific anti-Bax antibody (6A7) [53].
These events are inhibited in cells over-expressing Hsp70.
However, Hsp70 was unable to prevent cell death after
mitochondrial disruption and subsequent caspase 3 activation,
indicating that Hsp70 acted upstream of mitochondria by
inhibiting events leading to Bax activation and thereby
preventing the release of pro-apoptotic proteins from mito-
chondria. Of note, a recent study reported that Bax and Bak
could be directly activated by heat [55]. Taken together, these
results suggest that heat can induce conformational changes in
Bax leading to its translocation to mitochondria.1.4.2. BH3-only proteins
The BH3-only proteins (BOPs) have an essential role in the
initiation of apoptosis in C. elegans [56], mice [57] and human
cells [58]. A study of the phenotypes of transgenic mouse
combined with genetic analyses support the idea that BOPs are
specific sensors of different signals of apoptosis and convey the
apoptotic signal to the different multidomain pro-apoptotic
proteins [57,59–69]. For example, Bim and Bad are activated
after cytokines deprivation [60–62], Noxa and Puma are
activated after genomic DNA damage [63,64], Bmf is activated
by anoikis and UV-irradiation [65] and Bid is activated by the
death receptor Fas [16,66].
BOPs mediate the Bax-dependent cell death pathway by
acting upstream as sensors of different apoptotic stimuli [67–
69]. Recent studies with BH3 peptides have suggested that there
are two subgroups in the BOPs, leading to the classification of
BOPs as either death agonists or survival antagonists: the Bid-
like proteins (Bid, Bim) that can directly activate Bax and Bak
and the Bad-like proteins (Bad, Bik) that sensitize cells to
apoptosis by inhibiting the Bcl-2/Bax interaction [70,71].
Some BOPs activate apoptosis by inhibiting anti-apoptotic
members of the Bcl-2 family by formation of mitochondrial
hetero-dimers Bcl-2 (or Bcl-xL)/BOP, leading to the activation
of Bax [57,72]. NMR studies have shown a possible interaction
of Bcl-2 and Bcl-xL with Bad in vitro [73] and several studies
have shown a Bim/Bcl-2 and Bim/Bcl-xL interactions [61,74].
On the other hand, some proteins of the BOP group, like Bid,
were shown to directly interact with Bax [75]. However,
although binding of BOPs to their anti-apoptotic relatives has
been well documented, the direct interaction of BOPs such as
Bid or Bim with Bax has only recently been reported
[32,76,77]. Bid could interact with the Hα1 of Bax, leading
to Bax activation as measured by the binding of the
conformation-specific antibody 6A7 and the release of
cytochrome c. Furthermore, a mutation in the Bid–BH3
domain, Arg84Gly, was found to abrogate these effects and
this effect can be mirrored by a Asp33Ala mutation in the Hα1
of Bax [76]. Of note, the latter mutation has been found to
disrupt the salt bridge formed between the Hα1 of Bax and BH3
domain suggesting that the Bid–BH3 domain could induce Bax
conformational changes, at least partially, by disrupting this
endogenous salt bridge by competition for the Hα1 of Bax [24].
1.4.3. Inhibitors and activators of Bax
To identify proteins that would selectively bind to Bax,
numerous yeast two-hybrid screens were performed.
1.4.4. Humanin
Humanin (Hn), a 3 kDa peptide, was first identified as an
anti-apoptotic peptide that inhibited presenilin-induced apopto-
sis in neuronal cells [78]. Hn was shown to impede the
translocation of Bax from the cytosol to the mitochondria
thereby protecting cells from apoptosis-inducing signals that
target the mitochondrial but not the non-mitochondrial, cell
death pathway [79]. Indeed, a knock-down in Hn expression
augmented the sensitivity of cells to apoptosis by increasing the
translocation of Bax to mitochondria. Surprisingly, there is a
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possible gene transfer from the mitochondrial to the nuclear
genome during evolution [79].
Two studies by Reed's group have shown that Hn was able to
bind to the extra long isoform of Bim (BimEL) and Bid thereby
abrogating their activation of Bax and Bak [80,81]. In vitro
protein–protein interaction assays, immunoprecipitation assays
and fluorescence polarization assays have been used to
demonstrate the binding of Hn to Bid. Moreover, Hn conserved
a protective activity in bax−/− mitochondria, indicating that Hn
could inhibit the tBid-induced release of apoptogenic factors
from this organelle in a Bax-independent manner. In the same
study, it was shown that the first 12 amino acids of Hn were
necessary and sufficient to bind and suppress tBid activity in
vitro and in vivo.
1.4.5. Ku70
Yeast two-hybrid screening allowed the identification of
Ku70 as an inhibitor of Bax [82]. Ku70 is a ubiquitous protein
present in the cytoplasm and nucleus and is a subunit of the Ku
antigen implicated in the reparation of non-homologous double-
stranded DNA. Independently, Ku70 appears to inhibit Bax.
Ku70 deficient mice are extremely sensitive to anti-cancer drugs
without having any effect on DNA repair and an increased
concentration of Ku70 has been detected in some cancers [83].
An over-expression of Ku70 inhibited the Bax-dependent
signaling pathway whereas the suppression of Ku70 increased
Bax-dependent apoptosis. This interaction of Ku70 and Bax
occurs via the C-terminus of Ku70 and the N-terminus of Bax
resulting in the cytosolic sequestration of Bax. Minimal
peptides inhibiting Bax were designed from the C-terminal
domain of Ku70 [84,85].
1.4.6. 14-3-3 proteins
Some isoforms of the cytosolic and highly conserved protein
14-3-3 (θ, ε, ζ) seem to regulate Bax function. Numerous
cellular processes (cell cycle, cell death, intracellular traffic) are
under the control of these proteins, which sequestrate regulatory
proteins by hetero-dimerization. The 14-3-3θ isoform can
interact directly with Bax and sequestrate Bax in the cytosol
[39]. This interaction requires both the N- and C-terminal
domains of Bax but does not require its phosphorylation. The
over-expression of 14-3-3θ decreases apoptosis induced by the
over-expression of Bax in 293T cells or by an agonist of death
receptors in HeLa cells. Conversely, during apoptosis, Bax is
liberated from 14-3-3θ by caspase-dependent mechanisms and
is translocated to the mitochondria.
1.4.7. Bif-1
By yeast two-hybrid using Bax as bait, a new interacting
protein was identified and called Bif-1 (Bax interacting factor 1)
[86,87]. Bif-1, a member of the endophilin B protein family is a
protein of 365 amino acids and its C-terminal domain (amino
acids 308 to 364) contains a region with a high similarity to the
SH3 domain (Src homology 3 domain) implicated in signal
transduction pathways and cellular communication. Bif-1
mRNA is expressed in several tissues such as heart, skeletalmuscle, kidneys and placenta [86]. There are controversial
results about Bif-1 function and effect on Bax.
Heim's group showed that Bif-1 could interact with Bax via
their N-terminal domains and co-localized with Bax in the
cytosol. However, the over-expression of Bif-1 had no influence
on Bax-dependent apoptosis in 293T and HeLa cells [87].
Wang's group suggested that Bif-1 was partially co-localized
with Bax and was involved in the activation of Bax-dependent
pathways. The interaction of Bif-1 with Bax via the N-terminal
domain induced a conformational change in Bax and its
translocalization to mitochondria [86].
Bif-1 was also shown to play a regulatory role in apoptotic
activation, not only of Bax, but also Bak [88]. Inhibition of the
endogenous expression of Bif-1 by siRNA abrogated Bax
conformational change, cytochrome c release and caspase 3
activation induced by various intrinsic death signals (adriamy-
cin, staurosporine, actinomycin D, tunicamycin). Bif-1 was
shown to interact with Bax on mitochondria but this association
decreased 24 h after tunicamycin treatment of MEFs, suggesting
the formation of a transitory Bif-1/Bax complex in response to
apoptotic stimuli. Furthermore, the suppression of Bif-1
expression had no effect on the cell death induced by
BaxΔS184, a conformational changed and mitochondria-
bound mutant, suggesting that Bif-1 was involved in Bax-
mediated apoptosis by controlling its recruitment to mitochon-
dria. Immunoprecipitation assays using an anti-Bak antibody
that recognized only the conformational altered Bak protein
showed that loss of Bif-1 prevented Bak activation induced by
tunicamycin or staurosporine treatment. Moreover, suppression
of Bif-1 expression was associated with an enhanced ability of
HeLa cells to form colonies in soft agar and tumors in nude mice
after implantation. These results suggest that Bif-1 may function
as a tumor suppressor.
1.4.8. Clusterin
Clusterin, also named apolipoprotein J or TRPM-2 (testos-
terone-repressed prostate message 2), is a glycoprotein that has
diverse functions, notably apoptosis regulation and is over-
expressed in several human cancers such as prostate cancers,
breast cancers and squamous cell carcinoma [89,90]. There are
two forms of clusterin: the cytoplasmic form of 60 kDa and the
secreted form of 40 kDa, which is a hetero-dimer consisting of
α and β chains. Unlike other inhibitors of Bax, clusterin
specifically interacts with conformation-altered Bax in response
to chemotherapeutic drugs, thus inhibiting the oligomerization
of Bax [91]. Indeed, immunocytochemistry and cell fractiona-
tion experiments showed that clusterin was mainly mitochon-
drial. Transfection experiments showed that clusterin provided
protection against apoptosis induced by etoposide or camp-
tothecin. Moreover, the 6A7 antibody that specifically detects
activated Bax co-immunoprecipitated clusterin in etoposide-
treated cells. Cross-linking experiments showed that this
interaction inhibited Bax oligomerization. Moreover, mutation
analyses showed that the α chain and not the β chain, of
clusterin interacted with Bax. Given that clusterin is widely
over-expressed in human cancers and induced by chemother-
apeutic drugs, these results suggest that disrupting the
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cancer therapy.
1.5. Bax oligomerization, mitochondrial permeabilization and
cytochrome c release
Activation of the pro-apoptotic proteins Bax and Bak lead to
their oligomerization and the permeabilization of the OMM.
Two models of permeabilization are proposed: the non-specific
rupture of the OMM or the formation of specific channels in the
OMM [92].
The first model implicates the rupture of the OMM after the
swelling of the mitochondrial matrix. This model is based on
different observations: the fall of Δψm and cytochrome c
release induced by the addition of Bax on isolated mitochondria
are inhibited by the addition of cyclosporine A, bongkrekic acid
and the calcium depletion, which inhibit the mitochondrial
permeability Transition Pore (mPTP) [93–95]. The opening of
this non-specific megachannel induces the fall of Δψm and the
swelling of the mitochondria that causes the rupture of the
OMM and the massive release of cytochrome c. However,
several studies show that swelling is not an absolute prerequisite
during the in vivo apoptosis [93,96] and cytochrome c release
has been shown to occur in the absence of mitochondrial
depolarization [97].
Bcl-2 family proteins have been proposed to be regulatory
elements of the mPTP by interaction between Bax/ANT
(adenosine nucleotide translocator) and Bax/VDAC (voltage
dependent anionic channel) thanks to the BH3 domain [98,99].Fig. 3. Schematic representation of Bax activation and its mitochondrial membrane
conformation (with the participation of cytosolic proteins such as Ku70) that does no
while Hα9 occludes from the Hα5–Hα6 pocket. Steps 2: the movement of ARTaroun
can interact with putative mitochondrial receptor(s) that may be of different natures (p
Hα9 and triggers the integration of Bax into the membrane. Steps 3: Hα5–Hα6 and H
oligomerization process. The insertion of Bax into mitochondria is associated with tIt was shown that only VDAC is essential for the apoptotic
function of Bax [98,100]. Bax, localized to mitochondria after
apoptotic stimuli, directly interacts with VDAC thus leading to
its opening and the release of cytochrome c whereas Bcl-xL
interaction with VDAC leads to its closure. However, the
diameter of VDAC is not enough large to permit cytochrome c
passage. It was then suggested that Bax could induce a
conformational change in the VDAC or, another possibility was
that Bax and VDAC together formed a megachannel. On the flip
side, Kroemer's group showed the importance of Bax/ANT
interaction [99,101]. Two-hybrid and co-immunoprecipitation
experiments suggest that these two proteins can interact.
Moreover, purified Bax and ANT are sufficient to induce
liposome permeabilization after atractyloside-treatment. The
oligomerization (homo-dimerization or multimerization) of Bax
seems to be needed to form channels. In this case, ANT
regulates the insertion and the oligomerization of Bax in the
OMM and cytochrome c release is dependent on the channel
characteristics of Bax.
Other studies have shown that VDAC or ANT do not
participate in mitochondrial clustering formed by Bax oligo-
merization [20,102,103]. An alternative model is based on
intrinsic characteristics of Bcl-2 protein family. 3-D structural
analyses of Bcl-xL revealed structural and functional simila-
rities with the diphtheria toxin and the bacterial colicine, which
can form channels [36]. Moreover this channel activity was
shown in lipidic membranes [104]. Later, it was shown that
Bax, tBid and Bcl-2 have similar structures and were able to
form channels in lipidic membranes [105–108]. Channelintegration during apoptosis. Step 1: the conformation of ART is blocked in a
t allow the exposition of Hα1. The latter helix is in close contact with BH3/Hα2,
d the flexible zone between Pro8 and Pro13 allows the exposition of Hα1, which
roteins, lipids) while the Hα5–Hα6, which is liberated from its interaction with
α9 are inserted in the OMM. Both Hα2 (BH3) and Hα9 might participate in the
he liberation of apoptogenic proteins from the intermembrane space.
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in three steps: association with membranes and orientation (with
decrease in pH and negatively charged lipids). Then the
amphipathic Hα5 and Hα6 are perpendicularly integrated into
the lipidic bilayer and the neighboring helices are folded like an
opened umbrella. Finally, the channel is formed by homo-
dimerization or oligomerization of the bacterial toxin [107].
Similarly, Bcl-2 family proteins form channels with their central
Hα5 and Hα6 at acidic non-physiologic pH. However, only Bax
has a channel activity in liposomes at neutral pH and must
undergo, like bacterial toxins, conformational changes in order
to be translocated to OMM. Antonsson et al. [20] showed that
Bax (BaxΔC) induced the release of a fluorescent probe from
liposomes and at neutral pH this event could be inhibited by the
addition of Bcl-2. Therefore, the channel characteristics of Bax
are different from those of Bcl-2. Besides, destabilization of
phospholipid membranes by Bax and especially by oligomers of
Bax, in the presence of calcium [109], seems to generate
channels with a diameter of 22 Å, which might be sufficient for
cytochrome c release [110,111]. The last model could explain
how oligomers of Bax permeabilize the OMM and induce the
release of apoptogenic factors from the intermembrane space to
the cytosol. Although the existence of such channels has not
been shown in vivo, patch-clamp experiments have suggested a
correlation between the apparition of a new ionic channel on
proteoliposomes made from OMM obtained from mammalian
apoptotic cells or from Bax-expressing yeast [112]. This
channel, named MAC (Mitochondrial Apoptosis-induced
Channel) is linked to Bax on mitochondria, its activity is
sensitive to the anti-apoptotic protein Bcl-2 and its largest
conductance implies a diameter enough large (≥4 nm) for the
diffusion of cytochrome c and molecules with higher molecular
weight. Alternatively, Bax and tBid can generate lipidic
channels enough large to permit the release of cytochrome c
[110,113]. It has been suggested that membrane permeabiliza-
tion needs the cooperation between Bax, tBid and lipids,
essentially cardiolipids, in order to permit Bax activity [102].
Models based on channel formation in the OMM allow for the
conservation of integrity and functionality of the inner
mitochondrial membrane [114].
2. Conclusion
Of the several hundreds of nuclear encoded proteins, which
compose the mitochondrion, Bax is somewhat special, as it
becomes mitochondrial only when a death sentence is passed on
the cell. This feature might not be restricted only to Bax as an
increasing number of proteins have been described to
translocate to this organelle during the first stages of apoptosis
and in due course, mitochondria take revenge by exporting
intrinsic proteins to the cytosol. Bax appears to be the orchestra-
conductor of this lethal exchange together with Bak, a
constitutive mitochondrial protein, with which Bax shares
many but not all functions. Bax is a fascinating protein as it
undergoes probably several distinct changes in conformations at
the onset of apoptosis before becoming fully integrated into the
OMM. As depicted in Fig. 3, several steps can be considered.First, the activation of Bax by various stimuli of different
natures (proteins, lipids, pH, heat…), which causes a conforma-
tional change in Bax “en route” to the mitochondria; second, the
interaction of Bax with putative receptors (lipids, proteins) in
the OMM resulting in the association and presumable
integration into mitochondria; third, the acquisition of a
membrane embedded conformation, which is associated with
the oligomerization of Bax and the release of mitochondrial
proteins such as cytochrome c or AIF. Many questions remain
open from this simplistic model. What are the partners of Bax
during this journey?What kind of changes in conformation does
Bax undergo, and where and when do they take place? The
answers of these questions are of importance not only for the
comprehension of apoptosis but may be also in other functions
in which Bax could be implicated such as the mitochondrial
fission or fusion. More importantly, they may be useful in the
design of new therapeutic tools as apoptosis is involved in many
pathologies (cancer, neurodegenerative diseases such as Parkin-
son, Huntington, Alzheimer's disease, amyotrophic lateral
sclerosis).
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